Evidence map›Paper›PMID 36254179›Full record

ReviewThe World Allergy Organization journal2022

Good clinical practice recommendations in allergen immunotherapy: Position paper of the Brazilian Association of Allergy and Immunology - ASBAI.

Fernando Monteiro Aarestrup, Ernesto Akio Taketomi, Clóvis Eduardo Santos Galvão, Elaine Gagete, Anna Caroline Nóbrega Machado Arruda, Gil Bardini Alves, Geórgia Véras de Araújo Gueiros Lira, Marcos Reis Gonçalves, Mariana Graça Couto Miziara, Sidney Souteban Maranhão Casado and 6 more

Open access · goldAbstract readReview
In one paragraph

Review in The World Allergy Organization journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Fernando Monteiro AarestrupFederal University of Juiz de Fora (UFJF), MG, Brazil.
Ernesto Akio TaketomiImmunology and Laboratory of Allergy and Clinical Immunology, Department of Immunology, Institute of Biomedical Sciences (ICBIM) of the Federal University of Uberlandia (UFU), Brazil.
Clóvis Eduardo Santos GalvãoClinical Immunology and Allergy Service, Clinics Hospital, Faculty of Medicine, University of Sao Paulo(HC/FMUSP), Brazil.
Elaine GageteAllergy and Immunology, Brazilian Medical Association (AMB) and ASBAI, Brazil.
Anna Caroline Nóbrega Machado ArrudaAllergy and Immunology, Brazilian Medical Association (AMB) and ASBAI, Brazil.
Gil Bardini AlvesDepartment of Immunotherapy, ASBAI, Brazil.
Geórgia Véras de Araújo Gueiros LiraMedical Sciences Center of the Federal University of Pernambuco (UFPE), Brazil.
Marcos Reis GonçalvesPediatric Allergy and Immunology by the Brazilian Society of Pediatrics (SBP), Brazil.
Mariana Graça Couto MiziaraJosé Alencar Child's Hospital, Brasilia, DF, Brazil.
Sidney Souteban Maranhão CasadoAllergy and Immunology, Brazil.
Simone Valladão CuriAllergy and Immunology, Brazil.
Veridiana Aun Rufino PereiraFaculty of Medicine, University of the City of São Paulo (UNICID), Brazil.
Valéria SalesFaculty of Medicine, Federal University of Rio Grande do Norte, Brazil.
Dirceu SoléPaulista School of Medicine, Federal University of São Paulo, Brazil.
Norma de Paula Motta RubiniFederal University of the State of Rio de Janeiro - UNIRIO, Brazil.
Emanuel Savio Cavalcanti SarinhoDepartment of Pediatrics, Clinics Hospital of the Federal University of Pernambuco (UFPE), Brazil.
Associação Brasileira de Alergia e Imunologia · BRUniversidade Cidade de São Paulo · BRUniversidade Federal de Pernambuco · BRUniversidade Federal de Uberlândia · BRUniversidade Federal do Estado do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Allergen Immunotherapy (AIT) represents one of the pillars in the treatment of allergic diseases. AIT is the only therapeutic strategy with curative potential, promoting the reduction of drug use and long-term symptom control even after the end of the treatment. The European Academy of Allergy, Asthma and Immunology (EAACI) guidelines, position papers of World Allergy Organization (WAO), and the US Practice Parameters are the leading official documents that set scientific standard for the use of AIT in the world. The use of AIT in Brazil has specific regional conditions due to the pattern of allergen sensitization, as well as genetic, socioeconomic, and cultural characteristics, climate conditions, and the availability of allergenic extracts. The most prevalent house dust mites are Objective: According to the current scientific literature adapted to the Brazilian reality, this position paper aims to establish the main recommendations for the good clinical practice parameters for AIT in Brazil. Methods: A systematic review using the Pub Med and Cochrane databases was performed, and the websites of major allergy and immunology organizations were consulted. The research was limited to English language literature and was conducted between March 30, 2002, and March 30, 2022. The terms used for the research were: Allergen Immunotherapy, sublingual immunotherapy (SLIT), subcutaneous immunotherapy (SCIT), venom-specific immunotherapy (VIT), and allergen extract. Results: The several recommendations that establish the clinical practices for AIT recommended by the main Allergy, Asthma and Immunology world organizations were analyzed and adapted to the Brazilian situation. Conclusion: This position paper establishes the main recommendations for the effective clinical practice of AIT in Brazil, using current knowledge of evidence-based medicine and precision medicine.

Indexed as

Clinical practiceHDMHouse dust miteSCITSLITSubcutaneous allergen immunotherapySublingual allergen immunotherapyVenom-specific immunotherapyVIT

Identifiers

PMID36254179
PMCPMC9513275
OpenAlexW4297183389

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.